An animal health company cut its quarterly loss 48% to $3.2 million
Zomedica Corp. (ZOMDF) reported a 48% reduction in its quarterly loss to $3.2 million, with record revenue of $9.9 million, up 22% year-over-year. The company saw growth in diagnostics (up 113%) and therapeutic devices (up 7%), while operating expenses decreased 21%. Cash burn improved by 32%, and liquidity stood at $40.9 million as of September 30, 2026, according to the company.
How this was made
The 30-second read
Why it matters
The earnings beat and loss reduction could attract speculative buying, but the small market cap may cause volatility.
Market read
First‑report earnings for a micro‑cap; modest trading relevance.
What to watch
Liquidity remains modest at $40.9 M and the business is still unprofitable, which could limit upside.
Background
Zomedica is an animal‑health company focused on equine and companion‑animal diagnostics and therapeutics, trading on the OTCQB.
Ticker impact
Zomedica Corp. released its Q3 2026 earnings, showing record revenue and a narrowed quarterly loss to $3.2 million.
likely upward pressure as investors price in improved profitability
The company cut its loss by 48% and posted record revenue, a material beat for a micro‑cap.
Market effects
Positive signal for the animal‑health diagnostics sector, may boost peer sentiment.
Limited to U.S. OTC market; minimal broader impact.
Low; relevance confined to niche veterinary‑tech investors.
Counterpoint
Despite improved numbers, the company remains cash‑burn heavy and may face execution risk.
Key entities
- ExecutiveLarry Heaton
Chief Executive Officer of Zomedica, quoted in the release.
